Irinotecan-involved regimens for advanced gastric cancer: A pooled-analysis of clinical trials

doi:10.3748/wjg.v16.i46.5889

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 46

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3252)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series, Tables (1-1) series.

Item

Count

PDF

335

HTML

2490

Figures (1-7)

221

Tables (1-1)

206

Sum=3252

Dec 14, 2010 (publication date) through Nov 13, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Dec 14, 2010; 16(46): 5889-5894
Published online Dec 14, 2010. doi: 10.3748/wjg.v16.i46.5889

Open in New Tab Full Size Figure Download Figure

Figure 1 Article search and riddling progression. RCTs: Randomized controlled trials.

Open in New Tab Full Size Figure Download Figure

Figure 2 Overall survival rate of patients with advanced gastric cancer after irinotecan-containing and nonirinotecan-containing combination chemotherapies. HR: Hazard ratio.

Open in New Tab Full Size Figure Download Figure

Figure 3 Time to treatment failure of patients with advanced gastric cancer irinotecan-containing and nonirinotecan-containing combination chemotherapies. HR: Hazard ratio.

Open in New Tab Full Size Figure Download Figure

Figure 4 Overall response rate of patients with advanced gastric cancer after irinotecan-containing and nonirinotecan-containing combination chemotherapies. RR: Risk ratio.

Open in New Tab Full Size Figure Download Figure

Figure 5 Grade 3/4 haematological toxicities (thrombocytopenia) in patients with advanced gastric cancer after irinotecan-containing and nonirinotecan-containing combination chemotherapies. RR: Risk ratio.

Open in New Tab Full Size Figure Download Figure

Figure 6 Grade 3/4 gastrointestinal toxicities (diarrhea) in patients with advanced gastric cancer after irinotecan-containing and nonirinotecan-containing combination chemotherapies. RR: Risk ratio.

Open in New Tab Full Size Figure Download Figure

Figure 7 Funnel plots and Egger’s linear regression test showing the potential publication bias in diagnosis of advanced gastric cancer[22]. RR: Risk ratio.

Citation: Wang DL, Gu DY, Huang HY, Xu Z, Chen JF. Irinotecan-involved regimens for advanced gastric cancer: A pooled-analysis of clinical trials. World J Gastroenterol 2010; 16(46): 5889-5894
URL: https://www.wjgnet.com/1007-9327/full/v16/i46/5889.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i46.5889